Prof. Hartmut J. Ehrlich, MD, has more than 35 years of experience in leading positions in the biopharmaceutical industry
In his role as VP and Head of Global Research and Development at Baxter Biosciences, he has overseen the development and regulatory approval of key biologics in the specialty areas of hemophilia, thrombosis, immunology, neurology, oncology, biosurgery and vaccines, and has brought novel therapies to patients with substantial medical needs. He also successfully built and advanced a portfolio with over 50 programs in nonclinical and clinical development. He joined Abivax as of the founding of the Company in 2013 and successfully managed the IPO on the Euronext exchange in Paris in 2015, raising EUR 57.7M. As the CEO of Abivax, Hartmut drove the development of Abivax’s product portfolio, focusing on chronic inflammatory diseases. The most advanced drug candidate of Abivax, obefazimod, is currently in phase 3 clinical trials for the treatment of ulcerative colitis, a chronic inflammatory bowel disease.
Hartmut lived and worked in the US, The Netherlands, Germany, Switzerland, Austria and France. He contributed to more than 120 peer-reviewed articles and book chapters and authored and coauthored over 400 abstracts that were presented at scientific meetings.
